Intravitreal Implants


·         Dexamethasone intravitreal implant (DEX implant; Ozurdex, Allergan, Irvine, CA)
o   delivers the steroid intravitreally for 6 months
o   consists of poly (lactic-co-glycolic acid), a DEgradable polyester and dexamethasone
o   single-use applicator through a 22-gauge
o   uveitis and macular edema caused by retinal vein occlusion
o   350 µg and 700 µg version
o   Uses NOVADUR Delivery system
o   GENEVA (dexamethasone implant) study: Global Evaluation of implantable dexamethasone in retinal Vein occlusion with macular edema (GENEVA) study

·         Vitrasert ganciclovir implant
o   poly(vinyl alcohol) and poly(ethylene vinyl acetate)
o   delivers the medication for approximately 32 weeks (8 months) and has been shown to halt the progression of CMV
o   nondegradable
o   5/4.5 mg implant
o   Releases 1 mcg/ hour
o   Approaches concentration of 4 ug/ml intravitreal

·         Retisert fluocinolone implant
o   blend of the drug with poly(vinyl alcohol) and methylcellulose
o   0.59 mg pellet embedded in a nonbiodegradable scaffold designed to be implanted in the vitreous cavity via a sclerotomy and anchored by a suture to the eye wall
o   releases drug at steady state between 0.3 and 0.4µg/day for approximately 30 months
o   used most commonly for treatment of chronic non-infectious posterior uveitis.
o   Studied for DME also

·         Iluvien fluocinolone implant
o   narrow cylinder 3.5 × 0.37 mm
o   25-gauge
o   lowest dose format (0.2 µg/day)
o   higher-dose (0.5 µg/day) system
o   FAVOR (iluvien) study

·         I-vation triamcinolone implant
o   helical screw coated with triamcinolone acetonide that delivers the drug intravitreally for 36 months
o   25-gauge
o   drug is entirely within the coating on the helical structure and not within the bulk of the device

·         ECT CNTF Implant
o   which allows the intravitreal implantation of a chamber containing live cells programmed to release CNTF
o   1.5 ng/day
o   possible efficacy for age-related macular degeneration (AMD) involving geographic atrophy and for RP
o   2 years or more

·         ECT technology anti-VEGF implant
o   NT-503
o   For ARMD

·         Brimonidine Intravitreal Implant
o   Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
o   This is a randomized, double-masked, dose-response, sham-controlled evaluation of the safety and efficacy of brimonidine tartarate intravitreal implant in patients with geographic atrophy from age-related macular degeneration. It is hypothesized that the implant may promote the release of neuroprotective factors that may slow the progression of retinal degenerative disease.

- compiled & published by Dr Dhaval Patel MD AIIMS